Because of the substantial role of mitochondrial dysfunction in PD, mitochondrion-targeted therapeutics may facilitate the development of novel drugs for treating PD (Camilleri and Vassallo, 2014; Park et al., 2018; Grünewald et al., 2019; Bai et al., 2020), and parkin may be an important mitochondrial target for expanding our understanding of the molecular mechanisms of mitochondrial dysfunction in PD therapy. The gene discussed is PRKN; the disease is Parkinson disease.